专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006069242A2 FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF 审中-公开
标题翻译：熔化的吡唑衍生物及其代谢相关疾病的治疗方法
公开(公告)号：WO2006069242A2
公开(公告)日：2006-06-29
申请号：PCT/US2005046599
申请日：2005-12-22
申请人： ARENA PHARM INC , BOATMAN DOUGLAS P , SCHRADER THOMAS O , SEMPLE GRAEME , SKINNER PHILIP J , JUNG JAE-KYU
发明人： BOATMAN DOUGLAS P , SCHRADER THOMAS O , SEMPLE GRAEME , SKINNER PHILIP J , JUNG JAE-KYU
CPC分类号： C07D403/04 , C07D209/80 , C07D209/88 , C07D231/54 , C07D265/36 , C07D471/04 , C07D471/14
摘要： The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of a-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.
摘要翻译：本发明涉及式（Ia）的某些稠合吡唑衍生物及其药学上可接受的盐，其表现出有用的药理学性质，例如作为RUP25受体的激动剂。本发明还提供含有本发明化合物的药物组合物，以及使用本发明化合物和组合物治疗代谢相关疾病包括血脂异常，动脉粥样硬化，冠心病，胰岛素抵抗，2型糖尿病，综合征-X等。此外，本发明还提供了本发明化合物与其它活性剂如属于α-葡糖苷酶抑制剂类，醛糖还原酶抑制剂，双胍类，HMG-CoA还原酶抑制剂，角鲨烯合成抑制剂，贝特类，LDL分解代谢增强剂，血管紧张素转换酶（ACE）抑制剂，胰岛素分泌增强剂，DP受体拮抗剂等。

2. 发明申请

WO2005051937A3 4-OXO-4,5-DIHYDRO-FURAN-2-CARBOXYLIC AND ACID DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF 审中-公开
标题翻译： 4-氧-4,5-二氢呋喃-2-羧酸和酸衍生物及其与代谢相关疾病的治疗方法
公开(公告)号：WO2005051937A3
公开(公告)日：2005-09-15
申请号：PCT/US2004038920
申请日：2004-11-18
申请人： ARENA PHARM INC , JUNG JAE-KYU , SEMPLE GRAEME , JOHNSON BENJAMIN R
发明人： JUNG JAE-KYU , SEMPLE GRAEME , JOHNSON BENJAMIN R
IPC分类号： C07D307/68 , C07D409/04 , C07D409/10 , A61K31/381 , A61P3/06
CPC分类号： C07D307/68 , C07D405/04 , C07D409/04 , C07D409/10
摘要： System for selecting a colour shade comprising a very small number of colour display cards with mixed shades of two or more colours. The system comprises means for selecting one shade among mixed shades, means for presenting the selected mixed shade as well as means for specifying the selected mixed shade for making paint in the desired colour tone.
摘要翻译：用于选择颜色阴影的系统，其包括具有两种或更多种颜色的混合阴影的非常少量的彩色显示卡。该系统包括用于在混合色调中选择一种色调的装置，用于呈现所选择的混合色调的装置以及用于指定所选择的混合色调以使油漆以期望色调的装置。

3. 发明申请

WO2005051937A8 4-OXO-4,5-DIHYDRO-FURAN-2-CARBOXYLIC AND ACID DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF 审中-公开
标题翻译： 4-氧代-4,5-二氢 - 呋喃-2-羧酸和酸衍生物及其代谢相关疾病的治疗方法
公开(公告)号：WO2005051937A8
公开(公告)日：2006-08-31
申请号：PCT/US2004038920
申请日：2004-11-18
申请人： ARENA PHARM INC , JUNG JAE-KYU , SEMPLE GRAEME , JOHNSON BENJAMIN R
发明人： JUNG JAE-KYU , SEMPLE GRAEME , JOHNSON BENJAMIN R
IPC分类号： C07D307/68 , C07D409/04 , C07D409/10
CPC分类号： C07D307/68 , C07D405/04 , C07D409/04 , C07D409/10
摘要： The present invention relates to certain 4-oxo-4,5-dihydro-furan-2-carboxylic acid and ester derivatives of Formula (I) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X, and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of a-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, and the like.
摘要翻译：本发明涉及式（I）的某些4-氧代-4,5-二氢呋喃-2-羧酸和酯衍生物及其药学上可接受的盐，其表现出有用的药理学性质，例如作为RUP25的激动剂受体。本发明还提供含有本发明化合物的药物组合物和使用本发明化合物和组合物治疗代谢相关疾病（包括血脂异常，动脉粥样硬化，冠心病，胰岛素抵抗，2型糖尿病，综合征-X等。此外，本发明还提供了本发明化合物与其它活性剂如属于α-葡糖苷酶抑制剂类，醛糖还原酶抑制剂，双胍类，HMG-CoA还原酶抑制剂，角鲨烯合成抑制剂，贝特类，LDL分解代谢增强剂，血管紧张素转换酶（ACE）抑制剂，胰岛素分泌增强剂等。

4. 发明专利

ES2929977T3 Moduladores del receptor cannabinoide 未知
公开(公告)号：ES2929977T3
公开(公告)日：2022-12-05
申请号：ES18159738
申请日：2012-02-24
申请人： ARENA PHARM INC
发明人： THATTE JAYANT , BLACKBURN ANTHONY C , HAN SANGDON , JONES ROBERT M , JUNG JAE-KYU , MONTALBAN ANTONIO GARRIDO , PAL BIMAN B , RUETER JAIMIE KARYN , STRAH-PLEYNET SONJA , THORESEN LARS , XIONG YIFENG , YUE DAWEI , ZHU XIUWEN
IPC分类号： C07D231/54 , A61K31/416 , A61K31/4439 , A61K31/497 , A61K31/661 , A61P29/00 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07F9/09
摘要： Se proporcionan ciertos métodos útiles en el tratamiento del dolor que comprenden administrar un compuesto de fórmula Ia y composiciones farmacéuticas del mismo que modulan la actividad del receptor cannabinoide CB2; (Traducción automática con Google Translate, sin valor legal)

5. 发明专利

DK3385252T3 Cannabinoidreceptormodulatorer 未知
公开(公告)号：DK3385252T3
公开(公告)日：2022-10-24
申请号：DK18159738
申请日：2012-02-24
申请人： ARENA PHARM INC
发明人： THATTE JAYANT , BLACKBURN ANTHONY C , HAN SANGDON , JONES ROBERT M , JUNG JAE-KYU , MONTALBAN ANTONIO GARRIDO , PAL BIMAN B , RUETER JAIMIE KARYN , STRAH-PLEYNET SONJA , THORESEN LARS , XIONG YIFENG , YUE DAWEI , ZHU XIUWEN
IPC分类号： C07D231/54 , A61K31/416 , A61K31/4439 , A61K31/497 , A61K31/661 , A61P29/00 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07F9/09

6. 发明专利

SG10201901293RA CANNABINOID RECEPTOR MODULATORS 未知
公开(公告)号：SG10201901293RA
公开(公告)日：2019-03-28
申请号：SG10201901293R
申请日：2010-08-27
申请人： ARENA PHARM INC
发明人： JONES ROBERT M , HAN SANGDON , THORESEN LARS , JUNG JAE-KYU , STRAH-PLEYNET SONJA , ZHU XIUWEN , XIONG YIFENG , YUE DAWEI
摘要： CANNABINOIDRECEPTOR MODULATORS The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CBI receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, 10 inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate 15 cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease. (NO SUITABLE FIGURE) -343-

7. 发明专利

NZ598288A Cannabinoid receptor modulators 未知
公开(公告)号：NZ598288A
公开(公告)日：2014-02-28
申请号：NZ59828810
申请日：2010-08-27
申请人： ARENA PHARM INC
发明人： JONES ROBERT M , HAN SANGDON , THORESEN LARS , JUNG JAE-KYU , STRAH-PLEYNET SONJA , ZHU XIUWEN , XIONG YIFENG , YUE DAWEI
IPC分类号： C07D231/54 , A61K31/416 , A61K31/4439 , A61K31/497 , A61K31/661 , A61P19/02 , A61P29/00 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07F9/09
摘要： IP No. 598288 The present disclosure relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present disclosure further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present disclosure and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer’s disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson’s disease. Compounds of the disclosure: (1aR,5aR)-2-(5-Chloro-pyridin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diazacyclopropa[a]pentalene-4-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide Phosphoric acid mono-(2-{ [(1aR,5aR)-2-(4-cyano-pyridin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carbonyl]-amino} -2-methyl-propyl) ester (1aR,5aR)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diazacyclopropa[a]pentalene-4-carboxylic acid ((S)-2,2-dimethyl-1-methylcarbamoyl-propyl)-amide (1aS,5aS)-(S)-2-Amino-3-methyl-butyric acid (S)-3,3-dimethyl-2-{ [2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carbonyl]-amino} -butyl ester (1aS,5aS)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diazacyclopropa[a]pentalene-4-carboxylic acid ((1S,2S)-2-hydroxy-indan-1-yl)-amide And (1aR,5aR)-2-(4-Fluoro-pyridin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diazacyclopropa[a]pentalene-4-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide

8. 发明专利

CU23691B7 DERIVADOS DE PIRAZOL FUSIONADO Y MÉTODOS DE TRATAMIENTO DE LOS DESÓRDENES RELACIONADOS CON EL METABOLISMO 未知
公开(公告)号：CU23691B7
公开(公告)日：2011-09-21
申请号：CU20070144
申请日：2007-06-20
申请人： ARENA PHARM INC
发明人： JUNG JAE-KYU , SKINNER PHILIP J , SEMPLE GRAEME , SCHRADER THOMAS O , BOATMAN P DOUGLAS
IPC分类号： C07D231/54
摘要： La presente invención se refiere a ciertos derivados de pirazol fusionado de fórmula (Ia), y a sus sales farmacéuticamente aceptables, que exhiben propiedades farmacológicas útiles, por ejemplo, como agonistas para el receptor RUP25. Por otra parte la presente invención proporciona composiciones farmacéuticas que contienen los compuestos de la invención, y métodos que usan los compuestos y composiciones de la invención en el tratamiento de desórdenes metabólico-relacionados, incluyendo dislipidemia, aterosclerosis, enfermedad coronaria, resistencia a la insulina, diabetes tipo 2, Síndrome-X y sus similares. Además, la presente invención también proporciona el uso de los compuestos de la invención en combinación con otros agentes activos tales como aquellos pertenecientes a la clase de los inhibidores alfa-glucosidasa, inhibidores de la aldosasa reductasa, biguanidas, inhibidores de la HMG-CoA reductasa, inhibidores de la síntesis de escualeno, fibratos, potenciadores del catabolismo LDL, inhibidores de la enzima convertidora de angiotensina (ACE), potenciadores de la secreción de insulina, antagonistas del receptor DP, y sus similares.

9. 发明专利

NZ555721A Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related disorders 未知
公开(公告)号：NZ555721A
公开(公告)日：2011-02-25
申请号：NZ55572105
申请日：2005-12-22
申请人： ARENA PHARM INC
发明人： BOATMAN DOUGLAS P , SCHRADER THOMAS O , SEMPLE GRAEME , SKINNER PHILIP J , JUNG JAE-KYU
IPC分类号： C07D231/54 , A61K31/4155 , A61K31/416 , A61P9/10 , C07D403/04
摘要： Disclosed herein are fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof wherein substituents are as defined within the specification. Such compounds exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also disclosed are pharmaceutical compositions containing said compounds and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. The use of the compounds of Formula (Ia) in combination with other active agents such as those belonging to the class of á-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like are further disclosed.

10. 发明专利

CU20070144A7 DERIVADOS DE PIRAZOL FUSIONADO Y MÉTODOS DE TRATAMIENTO DE LOS DESÓRDENES RELACIONADOS CON EL METABOLISMO 未知
公开(公告)号：CU20070144A7
公开(公告)日：2010-01-22
申请号：CU20070144
申请日：2007-06-20
申请人： ARENA PHARM INC
发明人： JUNG JAE-KYU , SKINNER PHILIP J , SEMPLE GRAEME , SCHRADER THOMAS O , BOATMAN P DOUGLAS
IPC分类号： C07D231/54
摘要： La presente invención se refiere a ciertos derivados de pirazol fusionado de fórmula (Ia), y a sus sales farmacéuticamente aceptables, que exhiben propiedades farmacológicas útiles, por ejemplo, como agonistas para el receptor RUP25. Por otra parte la presente invención proporciona composiciones farmacéuticas que contienen los compuestos de la invención, y métodos que usan los compuestos y composiciones de la invención en el tratamiento de desórdenes metabólico-relacionados, incluyendo dislipidemia, aterosclerosis, enfermedad coronaria, resistencia a la insulina, diabetes tipo 2, Síndrome-X y sus similares. Además, la presente invención también proporciona el uso de los compuestos de la invención en combinación con otros agentes activos tales como aquellos pertenecientes a la clase de los inhibidores alfa-glucosidasa, inhibidores de la aldosasa reductasa, biguanidas, inhibidores de la HMG-CoA reductasa, inhibidores de la síntesis de escualeno, fibratos, potenciadores del catabolismo LDL, inhibidores de la enzima convertidora de angiotensina (ACE), potenciadores de la secreción de insulina, antagonistas del receptor DP, y sus similares.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式